Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10;6(9):e143940.
doi: 10.1172/jci.insight.143940.

HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection

Affiliations

HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection

Yik Lim Kok et al. JCI Insight. .

Abstract

HIV-1 is capable of integrating its genome into that of its host cell. We examined the influence of the activation state of CD4+ T cells, the effect of antiretroviral therapy (ART), and the clinical stage of HIV-1 infection on HIV-1 integration site features and selection. HIV-1 integration sites were sequenced from longitudinally sampled resting and activated CD4+ T cells from 12 HIV-1-infected individuals. In total, 589 unique HIV-1 integration sites were analyzed: 147, 391, and 51 during primary, chronic, and late presentation of HIV-1 infection, respectively. As early as during primary HIV-1 infection and independent of the activation state of CD4+ T cells collected on and off ART, HIV-1 integration sites were preferentially detected in recurrent integration genes, genes associated with clonal expansion of latently HIV-1-infected CD4+ T cells, cancer-related genes, and highly expressed genes. The preference for cancer-related genes was more pronounced at late stages of HIV-1 infection. Host genomic features of HIV-1 integration site selection remained stable during HIV-1 infection in both resting and activated CD4+ T cells. In summary, characteristic HIV-1 integration site features are preestablished as early as during primary HIV-1 infection and are found in both resting and activated CD4+ T cells.

Keywords: AIDS/HIV; Molecular biology; T cells; Virology.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: DLB received honoraria from Gilead Sciences, Merck, and ViiV. HFG received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; and consulting/advisory board membership fees from Merck, ViiV, and Gilead. KJM received travel grants and honoraria from Gilead Sciences, Merck Sharp & Dohme, and ViiV. The University of Zurich has received research grants from Gilead Sciences, Roche, and Merck Sharp & Dohme for studies of which KJM serves as principal investigator.

Figures

Figure 1
Figure 1. Genomic features of HIV-1 integration site libraries from longitudinally sampled resting and activated CD4+ T cells obtained from HIV-1–infected individuals during primary and chronic HIV-1 infection and during periods on and off ART and PBMCs from late presenters.
(A) Genomic distribution of HIV-1 integration sites. Undetermined HIV-1 integration sites were caused by splice variants. (B) Pairwise comparison of genomic features associated with HIV-1 integration sites in the different cell populations. The Benjamini-Hochberg method was used to correct for multiple hypothesis testing. (C) The orientation of HIV-1 proviruses relative to the host gene transcription orientation. Only intragenic HIV-1 integration sites were considered. P values were calculated using the 2-tailed Fisher’s exact test: *, P < 0.05, **, P < 0.01.
Figure 2
Figure 2. Comparison of HIV-1 integration sites identified during primary HIV-1 infection with HIV-1 integration sites identified by Wagner et al. and Maldarelli et al.
(A) HIV-1 integration sites identified during primary HIV-1 infection were compared with HIV-1 integration sites described by Wagner et al. and Maldarelli et al. (27, 28), with particular focus on those described to be associated with clonal expansion of latently HIV-1–infected, resting CD4+ T cells. (B) HIV-1 integration sites in genes associated with clonal expansion of latently HIV-1–infected, resting CD4+ T cells as described by Wagner et al. and Maldarelli et al. (27, 28).
Figure 3
Figure 3. Cancer-related genes are overrepresented in HIV-1 integration sites during all clinical stages of HIV-1 infection, particularly in resting CD4+ T cells.
The distribution of HIV-1 integration sites in resting and activated CD4+ T cells during primary and chronic HIV-1 infection on and off ART was analyzed in comparison with cancer-related genes (allOnco list) in the Gene Expression Omnibus (GEO) database (40). For further comparison, the list of HIV-1 integration sites described by Wagner et al. and Maldarelli et al. (27, 28) were included. P values were calculated using the 2-tailed χ2 test: ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 4
Figure 4. Highly expressed genes are preferentially targeted by HIV-1 during all clinical stages of HIV-1 infection in both activated and resting CD4+ T cells.
The distribution of HIV-1 integration sites in resting and activated CD4+ T cells during primary and chronic HIV-1 infection on and off ART was analyzed in comparison with gene expression levels in different cell populations. The following gene expression data sets were obtained from the GEO database (40): (A) GSE60235, 4-hour unstimulated and 48-hour activated CD4+ T cells (41); (B) GSE9927, in vivo activated CD4+ T cells from viremic, untreated HIV-1–infected individuals (42); and GSE66214, HIV-1 central memory and transitional memory CD4+ T cells from nonviremic, treated HIV-1–infected individuals. Accordingly to their expression levels, the genes were distributed into 8 bins by expression levels, each bin containing 12.5% of all genes (12.5% is marked with a dotted line).

Similar articles

Cited by

References

    1. Deeks SG, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22(8):839–850. doi: 10.1038/nm.4108. - DOI - PMC - PubMed
    1. Siliciano JD, Siliciano RF. Recent developments in the effort to cure HIV infection: going beyond N = 1. J Clin Invest. 2016;126(2):409–414. doi: 10.1172/JCI86047. - DOI - PMC - PubMed
    1. Siliciano JD, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–728. doi: 10.1038/nm880. - DOI - PubMed
    1. Wong JK, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291–1295. doi: 10.1126/science.278.5341.1291. - DOI - PubMed
    1. Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–1300. doi: 10.1126/science.278.5341.1295. - DOI - PubMed

Publication types